Diana Ilić, UH Merkur, Zajčeva 19, 10000 Zagreb, Croatia,
Croat Med J. 2021 Feb 28;62(1):44-51. doi: 10.3325/cmj.2021.62.44.
Neuroendocrine tumors (NET) are a rare and heterogeneous group of neoplasms with variable biological behavior. They frequently metastasize to the liver, requiring active, multimodality treatment. Surgical resection, possible in only a minority of cases, was until recently the only potentially curative option. For unresectable NET with liver metastases, liver transplantation (LT) emerged as a potential curative treatment due to relatively slow growth and indolent behavior of the metastases. In this case series with literature review, we retrospectively analyzed the characteristics of 12 highly selected patients with metastatic NET disease as an indication for LT treated in our center. We also summarized the proposed prognostic factors, and evaluated and compared the existing selection criteria. The main poor prognostic factors in our patients were high grade NET and primary tumor in the pancreas. Inconsistent liver transplantation outcome parameters make it difficult to standardize patient selection criteria. There is a need for further studies that would fully elucidate the curative potential of LT in patients diagnosed with NET.
神经内分泌肿瘤（NET）是一组罕见且异质性的肿瘤，具有不同的生物学行为。它们经常转移到肝脏，需要积极的、多模式的治疗。手术切除，在少数情况下可能实现，直到最近一直是唯一潜在的治愈选择。对于无法切除的伴肝脏转移的 NET，肝移植（LT）由于转移灶生长相对缓慢且惰性而成为一种潜在的治愈治疗方法。在这项具有文献回顾的病例系列研究中，我们回顾性分析了在我们中心治疗的 12 名高度选择的转移性 NET 疾病患者的特征，这些患者的疾病指征适合 LT。我们还总结了提出的预后因素，并评估和比较了现有的选择标准。我们患者的主要不良预后因素是高级别 NET 和胰腺原发肿瘤。不一致的肝移植结果参数使得难以标准化患者选择标准。需要进一步的研究，以充分阐明 LT 在诊断为 NET 的患者中的治愈潜力。
